🔴 Xenetic Biosciences is trading 6.25% down in pre-market; no company-specific catalyst identified

Xenetic Biosciences is trading 6.25% down at $3.15, with no fresh company-specific announcement identified for August 20, 2026.

• Results released August 7 showed a second-quarter loss of $930,000, or $0.41 per share, on $661,000 in revenue.
• The decline comes despite stronger biotech-sector sentiment; neither sector trends nor broader market conditions clearly explain the move. Volume data was unavailable.